Orchestra BioMed Holdings Inc [OBIO] stock is trading at $5.24, down -2.06%. An important factor to consider is whether the stock is rising or falling in short-term value. The OBIO shares have gain 12.45% over the last week, with a monthly amount glided 38.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Orchestra BioMed Holdings Inc [NASDAQ: OBIO] stock has seen the most recent analyst activity on August 20, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on March 20, 2025, and set its price target to $12. On January 02, 2025, Barclays initiated with a Overweight rating and assigned a price target of $16 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $14 on August 22, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $15 as its price target on July 25, 2024. Jefferies started tracking with a Buy rating for this stock on January 19, 2024, and assigned it a price target of $14. In a note dated February 24, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $15 on this stock.
Orchestra BioMed Holdings Inc [OBIO] stock has fluctuated between $2.20 and $6.30 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Orchestra BioMed Holdings Inc [NASDAQ: OBIO] shares were valued at $5.24 at the most recent close of the market. An investor can expect a potential return of 129.01% based on the average OBIO price forecast.
Analyzing the OBIO fundamentals
Orchestra BioMed Holdings Inc [NASDAQ:OBIO] reported sales of 2.82M for the trailing twelve months, which represents a drop of -12.77%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -24.21%, Pretax Profit Margin comes in at -23.67%, and Net Profit Margin reading is -23.67%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is -2.89 and Total Capital is -2.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.03 points at the first support level, and at 4.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.44, and for the 2nd resistance point, it is at 5.64.
Ratios To Look Out For
For context, Orchestra BioMed Holdings Inc’s Current Ratio is 4.73. On the other hand, the Quick Ratio is 4.72, and the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 104.92, the price to book ratio is 6.76.
Transactions by insiders
Recent insider trading involved Hochman David P, See Remarks, that happened on Nov 14 ’25 when 5000.0 shares were purchased. Director, Aryeh Jason completed a deal on Sep 19 ’25 to buy 1000.0 shares. Meanwhile, Director Fain Eric S bought 5760.0 shares on Aug 25 ’25.
